Chill out chemo pain: new device may stop nerve damage

NCT ID NCT07064798

Recruiting now Symptom relief Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a device that cools and squeezes the arms and legs during chemotherapy to prevent nerve damage, which can cause numbness, tingling, and pain. Fifty adults with breast or gynecologic cancer receiving taxane chemo will wear the device during infusions. Researchers will check if it reduces nerve symptoms, how long people can tolerate it, and if it's safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Paxman Limb Cryocompression System (cooling and compression device)
What this could lead to: If it works, this could give patients a simple, drug-free way to prevent or reduce nerve damage from taxane chemotherapy.
What could go wrong: This is a small, early-stage study with only 50 people, so results may not apply to everyone. The device may be uncomfortable or cause skin issues, and it might not reduce nerve symptoms as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chemotherapy-induced neuropathy peripheral nervous system disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY CIPN - CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY TAXANE-INDUCED PERIPHERAL NEUROPATHY

Contacts and locations

Locations

Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.